| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 10 | 2021 | 3869 | 1.260 |
Why?
|
| Melanoma | 14 | 2023 | 5317 | 1.060 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 986 | 1.000 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 11 | 2021 | 992 | 0.930 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 223 | 0.810 |
Why?
|
| Melanoma, Experimental | 5 | 2020 | 368 | 0.790 |
Why?
|
| Tumor Microenvironment | 10 | 2021 | 2864 | 0.760 |
Why?
|
| Receptors, OX40 | 2 | 2019 | 50 | 0.720 |
Why?
|
| Tumor Escape | 2 | 2021 | 251 | 0.710 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.690 |
Why?
|
| Programmed Cell Death 1 Receptor | 9 | 2020 | 1048 | 0.660 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 323 | 0.610 |
Why?
|
| Glycolysis | 2 | 2020 | 519 | 0.550 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2019 | 1586 | 0.550 |
Why?
|
| Complement System Proteins | 1 | 2016 | 139 | 0.540 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 598 | 0.530 |
Why?
|
| Antibodies | 2 | 2015 | 838 | 0.510 |
Why?
|
| Immunotherapy | 12 | 2022 | 3341 | 0.500 |
Why?
|
| Neoplasms | 9 | 2023 | 15193 | 0.500 |
Why?
|
| Adoptive Transfer | 3 | 2012 | 446 | 0.470 |
Why?
|
| Interferon-gamma | 6 | 2018 | 1144 | 0.440 |
Why?
|
| Neoplasms, Experimental | 3 | 2012 | 750 | 0.420 |
Why?
|
| Chemokines | 2 | 2012 | 314 | 0.410 |
Why?
|
| Mice | 23 | 2023 | 34495 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 9 | 2023 | 6942 | 0.390 |
Why?
|
| Cell Line, Tumor | 17 | 2021 | 14551 | 0.380 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2010 | 56 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 5178 | 0.380 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.360 |
Why?
|
| Animals | 26 | 2023 | 59536 | 0.330 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2018 | 1763 | 0.330 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2016 | 1033 | 0.310 |
Why?
|
| Cell Movement | 2 | 2012 | 2466 | 0.300 |
Why?
|
| Galectin 3 | 1 | 2008 | 138 | 0.300 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2023 | 23 | 0.240 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2021 | 675 | 0.240 |
Why?
|
| Lung Neoplasms | 5 | 2020 | 11538 | 0.240 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 4143 | 0.230 |
Why?
|
| Cell Proliferation | 6 | 2021 | 7226 | 0.230 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2023 | 209 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 3821 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 8873 | 0.210 |
Why?
|
| Autoimmunity | 1 | 2023 | 263 | 0.210 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2020 | 78 | 0.200 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2021 | 39 | 0.200 |
Why?
|
| Dendritic Cells | 4 | 2019 | 1085 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 5319 | 0.190 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 68 | 0.190 |
Why?
|
| Gene Dosage | 1 | 2023 | 829 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 290 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2018 | 1249 | 0.190 |
Why?
|
| Chemokine CXCL10 | 2 | 2018 | 105 | 0.180 |
Why?
|
| Humans | 33 | 2024 | 261506 | 0.180 |
Why?
|
| B7-H1 Antigen | 5 | 2021 | 1022 | 0.180 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2019 | 28 | 0.180 |
Why?
|
| Antigens, Differentiation | 2 | 2019 | 238 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 202 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 479 | 0.170 |
Why?
|
| Cancer Vaccines | 3 | 2016 | 697 | 0.170 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2018 | 28 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2018 | 1073 | 0.160 |
Why?
|
| Electroporation | 1 | 2019 | 126 | 0.160 |
Why?
|
| Drug Synergism | 3 | 2018 | 1313 | 0.160 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2018 | 53 | 0.160 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 141 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1038 | 0.160 |
Why?
|
| HLA-A Antigens | 1 | 2018 | 102 | 0.150 |
Why?
|
| Signal Transduction | 8 | 2021 | 11965 | 0.150 |
Why?
|
| Up-Regulation | 4 | 2018 | 2450 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 1016 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.150 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 10331 | 0.150 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2016 | 17 | 0.150 |
Why?
|
| Heterografts | 1 | 2019 | 733 | 0.150 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1005 | 0.140 |
Why?
|
| Repressor Proteins | 2 | 2023 | 1664 | 0.140 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2017 | 142 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2024 | 1230 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 483 | 0.140 |
Why?
|
| Complement C3 | 1 | 2016 | 78 | 0.140 |
Why?
|
| Cytokines | 3 | 2018 | 2809 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 196 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2013 | 1283 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2012 | 673 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 2265 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 486 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 419 | 0.120 |
Why?
|
| Immune Tolerance | 3 | 2021 | 403 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1350 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 1226 | 0.120 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2023 | 4078 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1294 | 0.120 |
Why?
|
| Toll-Like Receptor 8 | 3 | 2007 | 21 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 617 | 0.110 |
Why?
|
| Mastocytoma | 1 | 2012 | 6 | 0.110 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 82 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2017 | 710 | 0.110 |
Why?
|
| Receptors, Odorant | 1 | 2012 | 47 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2011 | 261 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 984 | 0.100 |
Why?
|
| Oximes | 1 | 2013 | 175 | 0.100 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 657 | 0.100 |
Why?
|
| CD40 Antigens | 1 | 2012 | 104 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 60 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2173 | 0.100 |
Why?
|
| Chemokine CXCL1 | 1 | 2010 | 60 | 0.100 |
Why?
|
| Prognosis | 8 | 2021 | 21713 | 0.100 |
Why?
|
| Indoles | 2 | 2013 | 1009 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 1547 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 4367 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1121 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2330 | 0.090 |
Why?
|
| Luciferases | 1 | 2010 | 445 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 475 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 5395 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2012 | 1506 | 0.080 |
Why?
|
| Lactose | 1 | 2008 | 63 | 0.080 |
Why?
|
| Prostatic Neoplasms | 3 | 2012 | 5767 | 0.080 |
Why?
|
| Thiazoles | 1 | 2012 | 726 | 0.080 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7222 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 1724 | 0.080 |
Why?
|
| Imidazoles | 1 | 2013 | 999 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2013 | 1823 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1271 | 0.070 |
Why?
|
| Female | 11 | 2020 | 141928 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 1489 | 0.060 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 943 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2017 | 1987 | 0.060 |
Why?
|
| Cell Line | 3 | 2023 | 5114 | 0.060 |
Why?
|
| Lymphocyte Activation | 3 | 2019 | 1688 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4638 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6089 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2003 | 61 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 778 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2927 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2005 | 582 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2003 | 192 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2013 | 272 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 862 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5061 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 5159 | 0.050 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 3230 | 0.050 |
Why?
|
| Spleen | 1 | 2003 | 676 | 0.050 |
Why?
|
| Arginine | 1 | 2023 | 500 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2012 | 3518 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2019 | 80 | 0.040 |
Why?
|
| DNA Replication | 1 | 2023 | 744 | 0.040 |
Why?
|
| Alarmins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 717 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2023 | 1064 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Protein Binding | 2 | 2018 | 3438 | 0.040 |
Why?
|
| Male | 7 | 2018 | 123000 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 1013 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2018 | 208 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2003 | 2074 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6207 | 0.040 |
Why?
|
| Apoptosis | 3 | 2020 | 7591 | 0.040 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2018 | 343 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 423 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 3639 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 291 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1516 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 623 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 543 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2020 | 677 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 447 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2315 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2007 | 155 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2020 | 554 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 355 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2023 | 2203 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2016 | 5710 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4757 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 1301 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 443 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 665 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1582 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 995 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2012 | 110 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2522 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 46 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 150 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2012 | 55 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2012 | 88 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1331 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 973 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2013 | 160 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2012 | 88 | 0.030 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2011 | 17 | 0.030 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2011 | 34 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 71 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2013 | 314 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.020 |
Why?
|
| Mutation | 3 | 2018 | 15179 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1062 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 479 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 521 | 0.020 |
Why?
|
| Pyridones | 1 | 2013 | 348 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2012 | 546 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Dasatinib | 1 | 2012 | 862 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4532 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 842 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8865 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 14289 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9180 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2007 | 37 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 105 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2007 | 166 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 190 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 3472 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1533 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4233 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 250 | 0.020 |
Why?
|
| Poly G | 1 | 2005 | 1 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2005 | 39 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 17523 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3101 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2005 | 129 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2005 | 174 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 309 | 0.010 |
Why?
|
| Dysgammaglobulinemia | 1 | 2003 | 4 | 0.010 |
Why?
|
| Antibody-Producing Cells | 1 | 2003 | 15 | 0.010 |
Why?
|
| Aged | 2 | 2019 | 70117 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 15694 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6150 | 0.010 |
Why?
|
| Germinal Center | 1 | 2003 | 161 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.010 |
Why?
|
| Middle Aged | 2 | 2019 | 86204 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 486 | 0.010 |
Why?
|
| RNA Interference | 1 | 2005 | 1408 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2003 | 199 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 904 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 29902 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 1439 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 37905 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 13658 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 32848 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 3045 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 77950 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 15862 | 0.010 |
Why?
|